Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 104
of 6Next
1:

Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective.

Date RS, Stylianides NA, Pursnani KG, Ward JB, Mughal MM.

World J Surg Oncol. 2008 Jul 18;6:77.

PMID: 18644105 [PubMed - indexed for MEDLINE]

2:

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW.

Ann Surg Oncol. 2007 Jan;14(1):14-24.

PMID: 17072676 [PubMed - indexed for MEDLINE]

3:

The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.

Kosmadakis N, Visvardis EE, Kartsaklis P, Tsimara M, Chatziantoniou A, Panopoulos I, Erato P, Capsambelis P.

Surg Oncol. 2005 Aug;14(2):75-84. Review.

PMID: 15993051 [PubMed - indexed for MEDLINE]

4:

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Cesne AL.

Ann Surg Oncol. 2006 Dec;13(12):1596-603.

PMID: 16957966 [PubMed - indexed for MEDLINE]

5:

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID: 12600228 [PubMed - indexed for MEDLINE]

6:

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

PMID: 15985189 [PubMed - indexed for MEDLINE]

7:

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM.

J Clin Oncol. 2006 May 20;24(15):2325-31.

PMID: 16710031 [PubMed - indexed for MEDLINE]

8:

Management of gastrointestinal stromal tumours: a single-centre experience.

Butt J, Rowley S, Byrne PJ, Reynolds JV.

Ir J Med Sci. 2007 Sep;176(3):157-60. Epub 2007 Jun 28.

PMID: 17597335 [PubMed - indexed for MEDLINE]

9:

Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.

Gold JS, van der Zwan SM, Gönen M, Maki RG, Singer S, Brennan MF, Antonescu CR, De Matteo RP.

Ann Surg Oncol. 2007 Jan;14(1):134-42. Epub 2006 Nov 2. Erratum in: Ann Surg Oncol. 2007 Oct;14(10):3027.

PMID: 17080234 [PubMed - indexed for MEDLINE]

10:

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.

Wu TJ, Lee LY, Yeh CN, Wu PY, Chao TC, Hwang TL, Jan YY, Chen MF.

BMC Gastroenterol. 2006 Oct 24;6:29.

PMID: 17062131 [PubMed - indexed for MEDLINE]

11:

[How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?]

Stelzner S, Antoni C, Haroske G, Jacobasch L, Erk JU, Ludwig K.

Zentralbl Chir. 2005 Dec;130(6):554-61. German.

PMID: 16382404 [PubMed - indexed for MEDLINE]

12:

[A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)]

Miyake M, Takeda Y, Hasuike Y, Kashiwazaki M, Mishima H, Ikenaga M, Mano M, Takada Y, Hirota S, Tsujinaka T.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1791-4. Japanese.

PMID: 15553717 [PubMed - indexed for MEDLINE]

13:

An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors.

Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y, Nishida T.

Int J Clin Oncol. 2007 Oct;12(5):369-74. Epub 2007 Oct 22.

PMID: 17929119 [PubMed - indexed for MEDLINE]

14:

[Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate]

Haugland HK, Jebsen NL, Mannelqvist M, Skar R, Eide J, Øvrebø K, Horn A, Jensen DK, Monge OR, Lilleng PK.

Tidsskr Nor Laegeforen. 2005 Apr 7;125(7):868-72. Norwegian.

PMID: 15815732 [PubMed - indexed for MEDLINE]

15:

Gastrointestinal stromal tumors: imatinib and beyond.

Schnadig ID, Blanke CD.

Curr Treat Options Oncol. 2006 Nov;7(6):427-37. Review.

PMID: 17032555 [PubMed - indexed for MEDLINE]

16:

Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy.

Melichar B, Voboril Z, Nozicka J, Ryska A, Urminská H, Vanecek T, Michal M.

Intern Med. 2005 Nov;44(11):1163-8.

PMID: 16357454 [PubMed - indexed for MEDLINE]

17:

Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.

Kasper B, Kallinowski B, Herrmann T, Lehnert T, Mechtersheimer G, Geer T, Ho AD, Egerer G.

Dig Dis. 2006;24(1-2):207-11.

PMID: 16699280 [PubMed - indexed for MEDLINE]

18:

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.

McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6727-34.

PMID: 18006774 [PubMed - indexed for MEDLINE]

19:

Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.

Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC.

Surgery. 2003 Oct;134(4):656-65; discussion 665-6.

PMID: 14605627 [PubMed - indexed for MEDLINE]

20:

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.

J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.

PMID: 17458563 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 104
of 6Next